HONG KONG – Reviews for priority new drugs in Japan in 2017 took the shortest time in five years, amid the drug watchdog's efforts to cut review lag. The review time for priority new drugs in 2017 was 8.9 months, the shortest since 2013, according to a recent report by the Pharmaceuticals and Medical Devices Agency (PMDA).
HONG KONG – Iceland biopharmaceutical firm Alvotech ehf has joined hands with Japan's Fuji Pharma Co. Ltd. in a deal to commercialize the former's biosimilar portfolio in Japan. Alvotech will develop and supply a few biosimilars from its product pipeline, while Fuji will work on those products' registration and commercialization in Japan. Fuji injected an investment of undisclosed size into the Iceland firm.
HONG KONG – The lack of cross-border regulations and coordination on genetic editing in general – and gene editing on embryos specifically – has emerged a key concern for industry leaders and regulators and a timely topic at the Second International Summit on Human Genome Editing in Hong Kong on Tuesday.
HONG KONG – The lack of cross-border regulations and coordination on genetic editing in general – and gene editing on embryos specifically – has emerged a key concern for industry leaders and regulators and a timely topic at the Second International Summit on Human Genome Editing in Hong Kong on Tuesday.
HONG KONG – Reviews for priority new drugs in Japan in 2017 took the shortest time in five years, amid the drug watchdog's efforts to cut review lag. The review time for priority new drugs in 2017 was 8.9 months, the shortest since 2013, according to a recent report by the Pharmaceuticals and Medical Devices Agency (PMDA).
HONG KONG – Iceland biopharmaceutical firm Alvotech ehf has joined hands with Japan's Fuji Pharma Co. Ltd. in a deal to commercialize the former's biosimilar portfolio in Japan. Alvotech will develop and supply a few biosimilars from its product pipeline, while Fuji will work on those products' registration and commercialization in Japan. Fuji injected an investment of undisclosed size into the Iceland firm.
HONG KONG – Chinese biologics and biosimilars maker Bio-Thera Solutions Ltd. kicked off a phase III trial of its HER2 antibody-drug conjugate (ADC), BAT-8001, targeting HER2-positive metastatic cancer.
